Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chrishan S Samuel

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
Kidney International|September 23, 2022
Targeting angiopoietin-2 as a novel treatment option for kidney fibrosisChrishan S Samuel
Clinical Medicine & Research|November 24, 2005
Relaxin: antifibrotic properties and effects in models of diseaseChrishan S Samuel
Methods in Molecular Biology (Clifton, N.J.)|January 17, 2009
Determination of collagen content, concentration, and sub-types in kidney tissueChrishan S Samuel
Annals of the New York Academy of Sciences|May 7, 2009
Relaxin: an endogenous renoprotective factor?Tim D Hewitson, Chrishan S Samuel
Current Molecular Medicine|January 17, 2022
Immune Mechanisms and Related Targets for the Treatment of Fibrosis in Various OrgansAnita A Pinar, Chrishan S Samuel
Biochemical Pharmacology|December 30, 2021
Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directionsChrishan S Samuel, Robert G Bennett
Current Opinion in Nephrology and Hypertension|December 17, 2008
Relaxin and the progression of kidney diseaseChrishan S Samuel, Tim D Hewitson
Frontiers in Pharmacology|November 30, 2017
Editorial: Novel Therapeutic Targets and Emerging Treatments for FibrosisChrishan S Samuel, Timothy D Hewitson
Pharmacology & Therapeutics|February 12, 2014
Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosisSimon G Royce, Yuben Moodley, Chrishan S Samuel
Advances in Experimental Medicine and Biology|December 29, 2007
The effects of relaxin on extracellular matrix remodeling in health and fibrotic diseaseChrishan S Samuel, Edna D Lekgabe, Ishanee Mookerjee
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
Kidney International|September 23, 2022
Targeting angiopoietin-2 as a novel treatment option for kidney fibrosisChrishan S Samuel
Clinical Medicine & Research|November 24, 2005
Relaxin: antifibrotic properties and effects in models of diseaseChrishan S Samuel
Methods in Molecular Biology (Clifton, N.J.)|January 17, 2009
Determination of collagen content, concentration, and sub-types in kidney tissueChrishan S Samuel
Annals of the New York Academy of Sciences|May 7, 2009
Relaxin: an endogenous renoprotective factor?Tim D Hewitson, Chrishan S Samuel
Current Molecular Medicine|January 17, 2022
Immune Mechanisms and Related Targets for the Treatment of Fibrosis in Various OrgansAnita A Pinar, Chrishan S Samuel
Biochemical Pharmacology|December 30, 2021
Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directionsChrishan S Samuel, Robert G Bennett
Current Opinion in Nephrology and Hypertension|December 17, 2008
Relaxin and the progression of kidney diseaseChrishan S Samuel, Tim D Hewitson
Frontiers in Pharmacology|November 30, 2017
Editorial: Novel Therapeutic Targets and Emerging Treatments for FibrosisChrishan S Samuel, Timothy D Hewitson
Pharmacology & Therapeutics|February 12, 2014
Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosisSimon G Royce, Yuben Moodley, Chrishan S Samuel
Advances in Experimental Medicine and Biology|December 29, 2007
The effects of relaxin on extracellular matrix remodeling in health and fibrotic diseaseChrishan S Samuel, Edna D Lekgabe, Ishanee Mookerjee
Pageof 18